Doctor Alysha Elliott is a Research Fellow at the Centre for Superbug Solutions in the Institute for Molecular Bioscience at The University of Queensland. Dr Elliott began their research career in 2007 and has since been dedicated to multi-disciplinary drug discovery with a specific passion for anti-infective targeted research. Dr Elliott is highly experienced in infectious disease microbiology, structural biology of peptides, and molecular biology. Developing new antibiotics to treat drug resistant pathogens and investigating mechanisms of resistance in bacteria are Dr Elliott's core research activities.

Dr Elliott is the Program Coordinator for Microbiology and Screening for the Community for Open Antimicrobial Drug Discovery (CO-ADD), a global antibiotic discovery initiative that has screened >300,000 unique compounds via high throughput screening technologies for antimicrobial activity from over 270 research groups from 47 countries. Dr Elliott's antimicrobial drug development research has been funded by NHMRC, CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), the Wellcome Trust and the Queensland Government (Advance Queensland). They has published more than sixty research articles and is active in collaborating with industry and public private partnerships for translational outcomes.

Dr Elliott’s current focus is on alternative therapies to treat extensively drug resistant Gram-negative bacterial infections, in particular the use of potentiators (inactive or inefficient compounds when used alone as an antimicrobial) to restore activity of traditional antibiotics that are no longer effective due to the development of antimicrobial resistance.


Publications by Alysha Elliott

More information about Alysha Elliott